Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekt af colon leveret vitamin B2 på tarmmikrobiota og relaterede sundhedsbiomarkører hos raske ældre voksne

6. november 2026 opdateret af: dsm-firmenich Switzerland AG

The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

348

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Cork, Irland
        • Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
  2. Between 50 and 70 years of age.
  3. Has a BMI of between 18.5 - 30 Kg/m2.
  4. Participants have had a stable body weight (≤5 % change) over the past 3-months.
  5. Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
  6. Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
  7. Maintain current level of physical activity.
  8. Willing to consume the investigational product daily for the duration of the study.
  9. Female participants in menopause for at least the last one year. -

Exclusion Criteria:

  1. Are hypersensitive to any of the components of the test product.

  2. Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)

  3. Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.

  4. Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).

  5. Is a smoker or vaper.

  6. Vegetarian or vegan.

  7. Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).

  8. Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.

  9. Has a currently active eating disorder.

  10. Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.

  11. Is having a typical fibre intake >30 g fibre/day.

  12. Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.

  13. If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.

  14. Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.

  15. Has a current or history of any gastrointestinal cancer

  16. Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).

  17. Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).

  18. Have a current malignant disease or any concomitant end-stage organ disease.

  19. Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.

  20. Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.

  21. Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.

  22. If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).

  23. Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).

    -

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Low dose

Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Eksperimentel: Mid dose

Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Eksperimentel: high dose

Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Placebo komparator: Placebo

One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Faecal microbial composition
Tidsramme: from baseline to 12 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12

from baseline to 12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Alpha diversity
Tidsramme: from baseline to 12 weeks

Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12.

from baseline to 12 weeks
Beta diversity
Tidsramme: week 0 to week 12

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12

week 0 to week 12
Faecal microbial metabolites fatty acid content at baseline and week 12
Tidsramme: from baseline to 12 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12

from baseline to 12 weeks
Acetate, Propionate and Butyrate
Tidsramme: baseline and week 12

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12.

baseline and week 12
Intestinal inflammation
Tidsramme: from baseline to 12 weeks

Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12

from baseline to 12 weeks
Intestinal barrier integrity
Tidsramme: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Oxidative stress in blood
Tidsramme: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Inflammatory status in blood
Tidsramme: from baseline to 12 weeks

Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12.

from baseline to 12 weeks
Gastrointestinal symptoms
Tidsramme: from baseline to 12 weeks

Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12.

from baseline to 12 weeks
health-related quality of life
Tidsramme: from baseline to 12 weeks

Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12.

The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase.

from baseline to 12 weeks
Stool consistency
Tidsramme: from baseline to 12 weeks

Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12).

Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively.

from baseline to 12 weeks
Stool frequency
Tidsramme: from baseline to 12 weeks

Stool frequency, as reported in the daily eDiary app (at baseline and week 12).

from baseline to 12 weeks
Systemic vitamin status
Tidsramme: from baseline to 12 weeks

The concentration of B vitamins in blood at baseline

from baseline to 12 weeks
Faecal physiological pH and redox
Tidsramme: from baseline to 12 weeks

Faecal physiological parameters measured as pH and redox potential at baseline and at week 12.

from baseline to 12 weeks
Faecal microbial composition at week 4
Tidsramme: from baseline to 4 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4.

from baseline to 4 weeks
Alpha diversity at week 4
Tidsramme: baseline to Week 4.

Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4.

baseline to Week 4.
Beta diversity at week 4
Tidsramme: week 0 to week 4

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4

week 0 to week 4
Microbial metabolites at week 4
Tidsramme: from baseline to 4 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4.

from baseline to 4 weeks
Acetate, Propionate and Butyrate at week 4
Tidsramme: week 0 to week 4

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4.

week 0 to week 4

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Skin barrier integrity
Tidsramme: from baseline to 12 weeks

Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12.

from baseline to 12 weeks
Skin hydration
Tidsramme: from baseline to 12 weeks

Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12.

from baseline to 12 weeks
Objective skin-health
Tidsramme: from baseline to 12 weeks

Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12.

from baseline to 12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Prof Timothy Dinan, Cork University Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. december 2022

Primær færdiggørelse (Faktiske)

6. juli 2023

Studieafslutning (Faktiske)

6. juli 2023

Datoer for studieregistrering

Først indsendt

16. februar 2023

Først indsendt, der opfyldte QC-kriterier

27. marts 2023

Først opslået (Faktiske)

7. april 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. september 2023

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2020-11-11-VITB2

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .